Benzinga Pro data, Ovid Therapeutics (NASDAQ:OVID) reported Q1 sales of $66 thousand. Earnings fell to a loss of $13.36 million, resulting in a 16.09% decrease from last quarter. Ovid Therapeutics collected $46 thousand in revenue during Q4, but reported earnings showed a $11.50 million loss.

What Is ROCE?

Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Ovid Therapeutics posted an ROCE of -0.11%.

It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future.

For Ovid Therapeutics, a negative ROCE ratio of -0.11% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

Analyst Predictions

Ovid Therapeutics reported Q1 earnings per share at $-0.19/share, which did not meet analyst predictions of $-0.17/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.